EUCTR2008-001755-22-DE进行中（未招募）不适用
Stealth liposomal doxorubicin vs carboplatin/paclitaxel in patients with ovarian cancer recurrence between six and twelve months after previous platinum based chemotherapy: phase III multicenter randomized studyAmendment 2 title: a phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval in patients with ovarian cancer recurring between 6 and 12 months after previous platinum based chemotherapy - Engot-OV-1 MITO-8-Ovar 2.16
Philipps-University Marburg0 个研究点目标入组 250 人开始时间: 2010年7月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Histological or cytological diagnosis of ovarian cancer
- •Disease recurrence between 6 and 12 months after a first-line platinum based
- •Indication for chemotherapy, but no more than 2 previous lines of previous therapy
- •Life expectancy of more than 3 months
- •Age 18 years or older
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previous or concomitant malignant malignancy (excluding adequately treated
- •baso-or squamocellular carcinoma of the skin and carcinoma in situ of the cervix)
- •ECOG Performance Status ? 3
- •Previous treatment with stealth liposomal doxorubicin
- •Residual peripheral neuropathy > Grade 2
- •Heart disease (congestive heart failure, myocardial infarction within 6 months
- •from study entry, atrioventricular block of any grade, severe arrhythmias)
- •Neutrophils < 2000 x mm3, platelets < 100000 x mm3
- •Inadequate renal function (creatinine ? 1.25 x normal values) or liver function
- •(ALT or AST ? 1.25 x normal values)
- •Present or suspected hemorrhagic syndromes
- •Inability to comply with protocol and follow-up
- •Inability to access study site for clinical visits
- •Refusal of informed consent
- •Concomitant participation in any other trial of systemic therapy or previous
- •participation no longer than 30 days ago
研究者
相似试验
进行中（未招募）
不适用
A randomized international study testing the effect of prolonging platinum patients with ovarian cancer recurring between 6 and 12 months after previous platinum based chemotherapy on survival.ovarian cancer recurrenceMedDRA version: 14.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-001755-22-BEational Cancer Institute Naples, Italy250
进行中（未招募）
不适用
STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDOMIZED STUDY - MITO-8EUCTR2008-001755-22-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE250
进行中（未招募）
不适用
Paclitaxel + Bevacizumab versus doxorubicina liposomiale non pegilata (Myocet), cyclophosfamide e Bevacizumab as the first line treatment in HER-2 negative metastatic breast cancer. Multicenter randomized Study of phase IImetastatic breast cancer HER2 negativeMedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006176-39-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE
进行中（未招募）
3 期
Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free IntervalOvarian CancerNCT00657878National Cancer Institute, Naples215
进行中（未招募）
2 期
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast CancerEstrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerTriple-negative Breast CancerNCT02315196Rutgers, The State University of New Jersey62